Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
benign histology of the prostate
benign prostatic hyperplasia (BPH)
disease-specific mortality
prostate cancer
prostate-specific antigen (PSA)
transurethral resection of the prostate (TURP)
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
27
06
2022
received:
23
05
2022
accepted:
28
06
2022
pubmed:
18
8
2022
medline:
28
9
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
The oncological risks after benign histology on a transurethral resection of the prostate (TURP) remain largely unknown. Here, the risk of prostate cancer incidence and mortality following a benign histological assessment of TURP is investigated in a population-based setting. Between 1995 and 2016, 64,059 men in Denmark underwent TURP without prior biopsy of the prostate; 42,558 of these men had benign histology. The risks of prostate cancer, prostate cancer with a Gleason score ≥ 3 + 4, and prostate cancer-specific death were assessed with competing risks. Specific risks for pre-TURP prostate-specific antigen (PSA) levels at 10 and 15 years were visualized by locally estimated scatterplot smoothing. The median age at TURP was 72 years (interquartile range [IQR], 65-78 years), and the median follow-up was 15 years (IQR, 10-19 years). The 10-year risks of any prostate cancer and prostate cancer with a Gleason score ≥ 3 + 4 and the 15-year risk of prostate cancer death showed clear visual relations with increasing PSA. The 15-year cumulative incidence of prostate cancer-specific death after benign TURP was 1.4% (95% confidence interval [CI], 1.3%-1.6%) for all men and 0.8% (95% CI, 0.6%-1.1%) for men with PSA levels <10 ng/ml. The primary limitation was exclusion due to missing PSA data. Men with low PSA levels and a benign TURP can be reassured about their cancer risk and do not need to be monitored differently than any other men. Patients with high PSA levels can be considered for further follow-up with prostate magnetic resonance imaging. These findings add to the literature suggesting that normal histology from the prostate entails a low risk of death from the disease. There is little knowledge about the oncological risks after the surgical treatment of benign prostatic hyperplasia. This study shows a very low risk of adverse oncological outcomes in men with prostate-specific antigen (PSA) levels below 10 ng/ml at the time of transurethral resection of the prostate. Patients with higher PSA levels may need more extensive follow-up.
Sections du résumé
BACKGROUND
The oncological risks after benign histology on a transurethral resection of the prostate (TURP) remain largely unknown. Here, the risk of prostate cancer incidence and mortality following a benign histological assessment of TURP is investigated in a population-based setting.
METHODS
Between 1995 and 2016, 64,059 men in Denmark underwent TURP without prior biopsy of the prostate; 42,558 of these men had benign histology. The risks of prostate cancer, prostate cancer with a Gleason score ≥ 3 + 4, and prostate cancer-specific death were assessed with competing risks. Specific risks for pre-TURP prostate-specific antigen (PSA) levels at 10 and 15 years were visualized by locally estimated scatterplot smoothing.
RESULTS
The median age at TURP was 72 years (interquartile range [IQR], 65-78 years), and the median follow-up was 15 years (IQR, 10-19 years). The 10-year risks of any prostate cancer and prostate cancer with a Gleason score ≥ 3 + 4 and the 15-year risk of prostate cancer death showed clear visual relations with increasing PSA. The 15-year cumulative incidence of prostate cancer-specific death after benign TURP was 1.4% (95% confidence interval [CI], 1.3%-1.6%) for all men and 0.8% (95% CI, 0.6%-1.1%) for men with PSA levels <10 ng/ml. The primary limitation was exclusion due to missing PSA data.
CONCLUSIONS
Men with low PSA levels and a benign TURP can be reassured about their cancer risk and do not need to be monitored differently than any other men. Patients with high PSA levels can be considered for further follow-up with prostate magnetic resonance imaging. These findings add to the literature suggesting that normal histology from the prostate entails a low risk of death from the disease.
LAY SUMMARY
There is little knowledge about the oncological risks after the surgical treatment of benign prostatic hyperplasia. This study shows a very low risk of adverse oncological outcomes in men with prostate-specific antigen (PSA) levels below 10 ng/ml at the time of transurethral resection of the prostate. Patients with higher PSA levels may need more extensive follow-up.
Identifiants
pubmed: 35975979
doi: 10.1002/cncr.34407
pmc: PMC9804454
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3674-3680Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
BJU Int. 2016 Jun;117(6):883-9
pubmed: 26823232
Lancet Oncol. 2017 Feb;18(2):221-229
pubmed: 28094199
Eur Urol. 2021 Nov;80(5):567-572
pubmed: 34294510
Lancet. 1974 Jul 20;2(7873):115-7
pubmed: 4135500
BJU Int. 2009 May;103(9):1190-4
pubmed: 19076142
Eur Urol Oncol. 2019 Nov;2(6):716-722
pubmed: 31411967
Eur Urol. 2011 Oct;60(4):691-8
pubmed: 21705134
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Scand J Public Health. 2011 Jul;39(7 Suppl):26-9
pubmed: 21775346
J Natl Cancer Inst. 1974 Aug;53(2):335-40
pubmed: 4843266
BMJ Open. 2020 Dec 18;10(12):e040965
pubmed: 33371032
BJU Int. 1999 Jul;84(1):37-42
pubmed: 10444122
Cancer. 2003 Oct 15;98(8):1727-34
pubmed: 14534890
Cochrane Database Syst Rev. 2019 Dec 3;12:CD009629
pubmed: 31792928
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
JAMA Oncol. 2022 Jul 1;8(7):1019-1026
pubmed: 35587340
Eur Urol. 2019 Mar;75(3):358-367
pubmed: 30580902
Medicine (Baltimore). 2016 May;95(18):e3493
pubmed: 27149447
Cancer. 1994 Oct 15;74(8):2347-51
pubmed: 7522950
Clin Epidemiol. 2016 Sep 27;8:351-360
pubmed: 27729813
Can Urol Assoc J. 2010 Oct;4(5):310-6
pubmed: 20944799
J Urol. 2022 Jul;208(1):100-108
pubmed: 35212571
Cancers (Basel). 2011 Nov 08;3(4):4127-38
pubmed: 24213129
Andrologia. 2022 Apr;54(3):e14332
pubmed: 34837229